scispace - formally typeset
T

Tobias Schmelzle

Researcher at Novartis

Publications -  46
Citations -  6618

Tobias Schmelzle is an academic researcher from Novartis. The author has contributed to research in topics: Hippo signaling pathway & Transcription factor. The author has an hindex of 23, co-authored 41 publications receiving 5893 citations. Previous affiliations of Tobias Schmelzle include Harvard University & University of Basel.

Papers
More filters
Journal ArticleDOI

TOR, a Central Controller of Cell Growth

TL;DR: Findings reveal that the target of rapamycin TOR controls an unusually abundant and diverse set of readouts all of which are important for cell growth, suggesting that this conserved kinase is such a central regulator.
Journal ArticleDOI

Engineering tumors with 3D scaffolds.

TL;DR: This new biomimetic model may provide a broadly applicable 3D culture system to study the effect of microenvironmental conditions on tumor malignancy in vitro and in vivo.
Journal ArticleDOI

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

E. Robert McDonald, +99 more
- 27 Jul 2017 - 
TL;DR: A large-scale RNAi screen is conducted in which viability effects of mRNA knockdown were assessed for 7,837 genes using an average of 20 shRNAs per gene in 398 cancer cell lines, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features.
Journal ArticleDOI

CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions

TL;DR: It is shown that CRISPR-based screens have a significantly lower false-negative rate compared with RNAi- based screens, but have specific liabilities particularly in the interrogation of regions of genome amplification, therefore, this study provides critical insights for applying CRISpr-based screening toward the systematic identification of new cancer targets.